AGL Agilon Health, Inc. is a financial enigma, trading at a perplexing discount relative to its DCF value. The market seems to have priced in a dire outlook, as evidenced by a Forward P/E of -150.64 and an Earnings Yield of -41.49%, signaling deep skepticism about future profitability. The Altman Z-score of 1.67 suggests a precarious financial position, teetering on the edge of distress. Despite these red flags, the stock’s valuation metrics, such as Price/Sales at 0.16, hint at a potential undervaluation if the company can stabilize its operations.